Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/91135
Title: | Inflammasome activation-induced hypercoagulopathy : impact on cardiovascular dysfunction triggered in COVID-19 patients | Authors: | Gedefaw, L Ullah, S Leung, PHM Cai, Y Yip, SP Huang, CL |
Issue Date: | Apr-2021 | Source: | Cells, Apr. 2021, v. 10, no. 4, 916 | Abstract: | Coronavirus disease 2019 (COVID-19) is the most devastating infectious disease in the 21st century with more than 2 million lives lost in less than a year. The activation of inflammasome in the host infected by SARS-CoV-2 is highly related to cytokine storm and hypercoagulopathy, which significantly contribute to the poor prognosis of COVID-19 patients. Even though many studies have shown the host defense mechanism induced by inflammasome against various viral infections, mechanistic interactions leading to downstream cellular responses and pathogenesis in COVID-19 remain unclear. The SARS-CoV-2 infection has been associated with numerous cardiovascular disorders including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism. The inflammatory response triggered by the activation of NLRP3 inflammasome under certain cardiovascular conditions resulted in hyperinflammation or the modulation of angiotensin-converting enzyme 2 signaling pathways. Perturbations of several target cells and tissues have been described in inflammasome activation, including pneumocytes, macrophages, endothelial cells, and dendritic cells. The interplay between inflammasome activation and hypercoagulopathy in COVID-19 patients is an emerging area to be further addressed. Targeted therapeutics to suppress inflammasome activation may have a positive effect on the reduction of hyperinflammation-induced hypercoagulopathy and cardiovascular disorders occurring as COVID-19 complications. | Keywords: | Inflammation Hypercoagulopathy Cardiovascular complications COVID-19 NLRP3 |
Publisher: | Molecular Diversity Preservation International (MDPI) | Journal: | Cells | EISSN: | 2073-4409 | DOI: | 10.3390/cells10040916 | Rights: | © 2021 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). The following publication Gedefaw, L.; Ullah, S.; Leung, P.H.M.; Cai, Y.; Yip, S.-P.; Huang, C.-L. Inflammasome Activation-Induced Hypercoagulopathy: Impact on Cardiovascular Dysfunction Triggered in COVID-19 Patients. Cells 2021, 10, 916 is available at https://doi.org/10.3390/cells10040916 |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Gedefaw_Inflammasome_activation-induced.pdf | 1.02 MB | Adobe PDF | View/Open |
Page views
75
Last Week
0
0
Last month
Citations as of May 5, 2024
Downloads
24
Citations as of May 5, 2024
SCOPUSTM
Citations
19
Citations as of Apr 26, 2024
WEB OF SCIENCETM
Citations
17
Citations as of May 2, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.